XORTX Therapeutics Inc. Reports Increased R&D Expenses and Wider Net Loss for H1 2025; EPS Falls to $(0.38) from $(1.07)
I'm PortAI, I can summarize articles.
XORTX Therapeutics Inc. reported increased R&D expenses and a wider net loss for H1 2025. R&D expenses rose to $186,751 for Q2 2025, up from $67,683 in Q2 2024, totaling $463,060 for the first half of 2025 compared to $141,326 in 2024. The loss per share for Q2 2025 was $0.19, a shift from a gain of $0.06 in Q2 2024, while the loss per share for H1 2025 was $0.38, improved from a loss of $1.07 in 2024. No specific outlook was provided.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments